4.4 Article

Gamma-gliadin specific celiac disease antibodies recognize p31-43 and p57-68 alpha gliadin peptides in deamidation related manner as a result of cross-reaction

Journal

AMINO ACIDS
Volume 53, Issue 7, Pages 1051-1063

Publisher

SPRINGER WIEN
DOI: 10.1007/s00726-021-03006-7

Keywords

Celiac disease; Gliadin; Deamidation; Antibody; Serum reactivity; Cross-reactivity

Funding

  1. University of Debrecen
  2. European Union
  3. European Social Fund
  4. Interreg Danube CD SKILLS project [DTP571]
  5. [GINOP-2.3.2-15-2016-00015]
  6. [NKFI 120392]
  7. [EFOP-3.6.1-16-2016-00022]

Ask authors/readers for more resources

Celiac disease is characterized by a T-cell dependent enteropathy with antibodies targeting TG2-deamidated gamma-gliadin peptides. However, serum reactivity towards p31-43 and p57-68 peptides has been identified, which is due to cross-reactive gamma-gliadin specific antibodies. Cross-reactive antibodies recognizing disease-relevant alpha-gliadins were also found in CeD patients.
Celiac disease (CeD) is a T-cell-dependent enteropathy with autoimmune features where tissue transglutaminase (TG2)-mediated posttranslational modification of gliadin peptides has a decisive role in the pathomechanism. The humoral immune response is reported to target mainly TG2-deamidated gamma-gliadin peptides. However, alpha-gliadin peptides, like p57-68, playing a crucial role in the T-cell response, and p31-43, a major trigger of innate responses, also contain B-cell gliadin epitopes and gamma-gliadin like motifs. We aimed to identify if there are anti-gliadin-specific antibodies in CeD patients targeting the p31-43 and p57-68 peptides and to examine whether deamidation of these peptides could increase their antigenicity. We explored TG2-mediated deamidation of the p31-43 and p57-68 peptides, and investigated serum antibody reactivity toward the native and deamidated alpha and gamma-gliadin peptides in children with confirmed CeD and in prospectively followed infants at increased risk for developing CeD. We affinity-purified antibody populations utilizing different single peptide gliadin antigens and tested their binding preferences for cross-reactivity in real-time interaction assays based on bio-layer interferometry. Our results demonstrate that there is serum reactivity toward p31-43 and p57-68 peptides, which is due to cross-reactive gamma-gliadin specific antibodies. These gamma-gliadin specific antibodies represent the first appearing antibody population in infancy and they dominate the serum reactivity of CeD patients even later on and without preference for deamidation. However, for the homologous epitope sequences in alpha-gliadins shorter than the core QPEQPFP heptapeptide, deamidation facilitates antibody recognition. These findings reveal the presence of cross-reactive antibodies in CeD patients recognizing the disease-relevant alpha-gliadins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available